T cell kinetics and apoptosis in immune organs and mammary tumors of rats treated with cyclophosphamide and soluble tumor-associated antigens

In Vivo

Volumn 16, Issue 6, 2002, Pages 567-576

  Zusman, Itshak ^a   Kossoy, George ^b   Ben Hur, Herzl ^b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b ASSAF HAROFEH MEDICAL CENTER   (Israel)

Author keywords

Apoptosis; Bone marrow; Lymph nodes; Mammary tumors; Spleen; T lymphocytes; Thymocytes

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CYCLOPHOSPHAMIDE; DIMETHYLBENZ[A]ANTHRACENE; DOXORUBICIN; IMMUNOMODULATING AGENT; OXAZAPHOSPHORINE; SOLUBLE TUMOR ASSOCIATED ANTIGEN; TAMOXIFEN; UNCLASSIFIED DRUG; ALKYLATING AGENT; TUMOR ANTIGEN;

APOPTOSIS; BONE MARROW; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CELL KINETICS; CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MORPHOMETRICS; NONHUMAN; RAT; REVIEW; SPLEEN; T LYMPHOCYTE; THYMUS; VACCINATION; ACTIVE IMMUNIZATION; ANIMAL; DRUG COMBINATION; EXPERIMENTAL NEOPLASM; IMMUNOLOGY; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; IMMUNE SYSTEM; IMMUNOTHERAPY, ACTIVE; MAMMARY NEOPLASMS, EXPERIMENTAL; RATS; T-LYMPHOCYTES;

EID: 0036860566     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Morel A, De LaCoste A, Fernandez N, Berson A, Kaybanda M, Molina T, Briand P, Haddada H, Guillet JG, Antonie B, Viduier M and Kahn A: Does preventive vaccination with engineered tumor cells work in cancer-prone transgenic mice? Cancer Gene Therapy 5: 92-100, 1998.
2. Minev BR, Chavez FL and Mitchell MS: Cancer vaccines: Novel approaches and new promise. Pharmacol Ther 81: 121-139, 1999.
3. Takada T, Kato K, Yagita H, Hamada H and Okumura K: Effects of immunization with tumor cells double transfected with interleukin-2 (IL-2) and interleukin-12 (IL-12) genes on artificial metastases of colon-26 cells in BALB/c mice. Clin Exp Metastasis 17: 125-130, 1999.
4. Ben-Hur H, Kossoy G, Sandler B and Zusman I: Vaccination with soluble low molecular weight tumour-associated proteins suppresses chemically-induced mammary tumorigenesis in rats. In Vivo 14: 551-554, 2000.
5. Ben-Hur H, Kossoy G and Zusman I: Soluble low-molecular-mass tumor-associated proteins promote the suppression of mammary tumors by cyclophosphamide. Int J Oncol 19: 407-411, 2001.
6. Ben-Hur H, Kossoy G and Zusman I: Soluble low-molecular-mass tumor associated proteins promote the suppression of mammary tumors by tamoxifen and prevent its toxic effect. Int J Oncol 20: 413-417, 2002.
7. Zhang J and Russell SJ: Vectors for cancer gene therapy. Cancer Metast Rev 15: 385-401, 1996.
8. Oprea M and Perelson AS: Exploring the mechanisms of primary antibody responses to T cell-dependent antigens. J Theor Biol 181: 215-236, 1996.
9. Ben-Hur H, Plonsky E, Gurevich P, Berman V, Tendler Y, Moriel E, Guy M, Sandler B, Rozenberg V, Zusman R and Zusman I: Morphological and morphometric studies of the splenic antitumor immune response, elicited by liposome-covering soluble p53 antigen, in chemically induced rat colon cancer. Int J Mol Med 3: 545-549, 1999.
10. Xu M, Kumar D, Stass SA and Mixson AJ: Gene therapy with p53 and a fragment of thrombospondin I inhibits human breast cancer in vivo. Mol Genetics Metab 63: 103-109, 1998.
11. Kossoy G, Yarden G, Be-Hur H, Kossoy N, Stark A, Madar Z and Zusman I: Comparative effects of dimethylbenz(a)anthracene and a 15% olive-oil diet on cellular components and expression of apoptosis-related proteins in the spleen and mammary gland tumors in rats. Oncol Rep 8: 435-439, 2001.
12. Gabriel A, Namyslowski G, Ziolkowski A, Morawski K, Steplewska-Mazur K and Urbaniec P: Immunohistochemical analysis of lymphocytic infiltration in the tumor microenvironment in patients operated on for laryngeal cancer. Eur Arch Oto Rhino Laryngol 256: 384-387, 1999.
13. Sheu BC, Hsu SW, Ho HN, Lin RH, Torng PL and Huang SC: Reversed CD4/CD8 ratios of tumor-infiltrating lymphocytes are correlated with the progression of human cervical carcinoma. Cancer 86: 1537-1543, 1999.
14. Zehntner S, Townsend W, Parkes J, Schmidt C, Down M, Bell J, Mulligan R, O'Rourke M, Ellem K and Thomas R: Tumor metastasis biopsy as a surrogate marker of response to melanoma immunotherapy. Pathology 31: 116-122, 1999.
15. Nasu Y, Bangma CH, Hull GW, Lee HM, Hu J, Wang J, McCurdy MA, Shimura S, Yang G, Timme TL and Thompson TC: Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: Suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model. Gene Ther 6: 338-349, 1999.
16. Manki A, Ono T, Uenaka A, Seino Y and Nakayama E: Vaccination with multiple antigen peptide as rejection antigen peptide in murine leukemia. Cancer Res 58: 1960-1964, 1998.
17. Toomey D, Harmey J, Condron C, Kay E and Bouchier-Hayes D: Phenotyping of immune cell infiltrates in breast and colorectal tumours. Immunol Invest 28: 29-41, 1999.
18. Drake DR, Moser JM, Hadley A, Altman JD, Maliszewski C, Butz E and Lukacher AE: Polyomavirus-infected dendritic cells induce antiviral CD8(+) T lymphocytes. J Virol 74: 4093-101, 2000.
19. Jonjic N, Valkovic T, Lucin K, Iternicka Z, Krstulja M, Mustac E, Dobi-Babic R, Sasso F and Melato M: Comparison of microvessel density with tumor associated macrophages in invasive breast carcinoma. Anticancer Res 18: 3767-3770, 1998.
20. Nath D, Hartnell A, Happerfield L, Miles DW, Burchell J, Taylor-Papadimitriou J and Crocker PR: Macrophage-tumour cell interactions: Identification of MUC1 on breast cancer cells as a potential counter-receptor for the macrophage-restricted receptor, sialoadhesin. Immunol 98: 213-219, 1999.
21. Harmey JH, Dimitriadis E, Kay E, Redmond HP and Bouchier-Hayes D: Regulation of macrophage production of vascular endothelial growth factor (VEGF) by hypoxia and transforming growth factor beta-1. Ann Surg Oncol 5: 271-278, 1998.
22. Leek RD, Hunt NC, Landers RJ, Lewis CE, Royds JA and Harris AL: Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. J Pathol 190: 430-436, 2000.
23. Valkovic T, Lucin K, Krstulja M, Dobi-Babic R and Jonjic N: Expression of monocyte chemotactic protein-1 in human invasive ductal breast cancer. Pathol Res Pract 194: 335-340, 1998.
24. Majori M, Poletti V, Curti A, Corradi M, Falcone F and Pesci A: Bronchoalveolar lavage in bronchiolitis obliterans organizing pneumonia primed by radiation therapy to the breast. J Allergy Clin Immunol 105: 239-244, 2000.
25. Nagai H, Hara I, Horikawa T, Fujii M, Kurimoto M, Kamidono S and Ichihashi M: Antitumor effects on mouse melanoma elicited by local secretion of interleukin-12 and their enhancement by treatment with interleukin-18. Cancer Invest 18: 206-213, 2000.
26. Negus RP, Stamp GW, Hadley J and Balkwill FR: Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am J Pathol 150: 1723-1734, 1997.
27. Heally JI and Goodnow CC: Positive versus negative signaling by lymphocyte antigen receptors. Ann Rev Immunol 16: 645-670, 1998.
28. Plate JMD, Shott S and Harris JE: Immunoregulation in pancreatic cancer patients. Cancer Immunol Immunother 48: 27-279, 1999.
29. Fischer WH, Straten PT, Terheyden P and Becker JC: Function and dysfunction of CD4+ T cells in the immune response to melanoma. Cancer Immunol Immunother 48: 363-370, 1999.
30. Ohtani H: Pathophysiologic significance of host reactions in human cancer tissue: Desmoplasia and tumor immunity. Tohoku J Exp Med 187: 193-202, 1999.
31. Balogh P and Kumånovics A: Tissue-associated phenotypic heterogeneity of peripheral B cells in mice. Immunol 86: 560-570, 1995.
32. Yamamoto M, Rennert P, McGhee JR, Kweon MN, Yamamoto S, Dohi T, Otake S, Bluethmann H, Fujihashi K and Kiyono H: Alternate mucosal immune system: Organized Peyer's patches are not required for IgA responses in the gastrointestinal tract. J Immunol 164: 5184-5191, 2000.
33. Ben-Hur H, Kossoy G, Zandbank J, Schneider DJ and Zusman I: Response of the immune system of mammary tumor-bearing rats to cyclophosphamide and soluble low-molecular mass tumor-associated antigens. The spleen and lymph nodes. Int J Mol Med 9: 311-316, 2002.
34. Camacho FI, Garcia JF, Sanchez-Verde L, Saez AI, Sanchez-Beato M, Mollejo M and Piris MA: Unique phenotypic profile of monocytoid B cells: Differences in comparison with the phenotypic profile observed in marginal zone B cells and so-called monocytoid B cell lymphoma. Am J Pathol 158: 1363-1369, 2001.
35. Blaschke V, Micheel B, Pabst R and Westermann J: Lymphocyte traffic through lymph nodes and Peyer's patches of the rat: B- and T-cell-specific migration patterns within the tissue, and their dependence on splenic tissue. Cell Tissue Res 282: 377-386, 1995.
36. Hernberg M: Lymphocyte subsets as prognostic markers for cancer patients receiving immunomodulative therapy. Medical Oncol 16: 145-153, 1999.
37. Ayoub JP, Palmer JL, Huh Y, Cabanillas F and Younes A: Therapeutic and prognostic implications of peripheral blood lymphopenia in patients with Hodgkin's disease. Leukemia Lymphoma 34: 519-527, 1999.
38. Whiteside TL: Signaling defects in T lymphocytes of patients with malignancy. Cancer Immunol Immunother 48: 346-352, 1999.
39. Cosiski-Marana HR, Santana Da Silva J and Moreira De Andrade J: NK cell activity in the presence of IL-12 is a prognostic assay to neoadjuvant chemotherapy in cervical cancer. Gynecol Oncol 78: 318-323, 2000.
40. Nagorsen D, Keilholz U, Rivoltini L, Schmittel A, Letsch A, Asemissen AM, Berger G, Buhr HJ, Thiel E and Scheibenbogen C: Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer. Cancer Res 60: 4850-4854, 2000.
41. Di Girolamo V, Laguens RP, Coronato S, Salas M, Spinelli O, Portiansky E and Laguens G: Quantitative and functional study of breast cancer axillary lymph nodes and those draining other human malignant tumors. J Exp Clin Cancer Res 19: 155-159, 2000.
42. Santin AD, Ravaggi A, Bellone S, Pecorelli S, Cannon M, Parham GP and Hermonat PL: Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix. Gynecol Oncol 81: 424-432, 2001.
43. Kossoy G, Ben-Hur H, Kossoy N and Zusman I: Effects of soluble low-molecular-mass proteins on spleen activity and cellular composition of infiltrates in rat mammary gland tumors. Int J Mol Med 7: 221-224, 2001.
44. Ben-Hur H, Kossoy G, Zanbank J and Zusman I: Response of the immune system of mammary tumor-bearing rats to cyclophosphamide and soluble low-molecular mass tumor-associated antigens. Rate of lymphoid infiltration and distribution of T lymphocytes in tumors. Int J Mol Med 9: 425-430, 2002.
45. Grobholz R, Verbeke CS, Schleger C, Kohrmann KU, Hein B, Wolf G, Bleyl U, Spagnoli GC, Coplan K, Kolb D, Iversen K and Jungbluth AA: Expression of MAGE antigens and analysis of the inflammatory T-cell infiltrate in human seminoma. Urol Res 28: 398-403, 2000.
46. Kath R, Blumenstengel K, Fricke HJ and Hoffken K: Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J Cancer Res Clin Oncol 127: 48-54, 2001.
47. Marzo AL, Lake RA, Robinson BW and Scott B: T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. Cancer Res 59: 1071-1079, 1999.
48. Li Q, Furman SA, Bradford CR and Chang AE: Expanded tumor-reactive CD4+ T-cell responses to human cancers induced by secondary anti-CD3/anti-CD28 activation. Clin Cancer Res 5: 461-469, 1999.
49. Kovacs E: The serum levels of IL-12 and IL-16 in cancer patients. Relation to the tumor stage and previous therapy. Biomed Pharmacother 55: 111-116, 2001.
50. Rice DC, Chapoval AI, Porter L and Nelson H: Induction of antitumor immunity after cure of pulmonary metastases, using staphylococcal enterotoxin B and bispecific antibody. Cancer Immunol Immunother 48: 230-238, 1999.
51. Singer A, Bosselut R and Bhandoola A: Signals involved in CD4/CD8 lineage commitment: Current concepts and potential mechanisms. Semin Immunol 11: 273-281, 1999.
52. King LB, Tolosa E, Lenczowski JM, Lu F, Lind EF, Hunziker R, Petrie HT and Ashwell JD: A dominant-negative mutant of c-Jun inhibits cell cyle progression during the transition of CD4(-)CD8(-) to CD4(+)CD8(+) thymocytes. Int Immunol 11: 1203-1216, 1999.
53. Eichhorst ST, Muerkoster S, Weigand MA and Krammer PH: The chemotherapeutic drug 5-fluorouracil induces apoptosis in mouse thymocytes in vivo via activation of the CD95(APO-1/Fas) system. Cancer Res 61: 243-248, 2001.
54. Gallo F, Morale MC, Sambataro D, Farinella Z, Scapaguini U and Marchetti B: The immune system response during development and progression of carcinogen-induced rat mammary tumors: Prevention of tumor growth and restoration of immune system responsiveness by thymopentin. Breast Cancer Res Treat 27: 221-237, 1993.
55. Ben-Hur H, Kossoy G, Kossoy N and Zusman I: Response of the immune system of mammary tumor-bearing rats to cyclosphosphamide and soluble low-molecular mass tumor-associated antigens. The bone marrow and thymus. Int J Mol Med 2002, in press.
56. Prockop S, Petrie HT: Cell migration and the anatomic control of thymocyte precursor differentiation. Semin Immunol 12: 435-444, 2000.
57. Punt JA, Suzuki H, Granger LG, Sharrow SO and Singer A: Lineage commitment in the thymus: Only the most differentiated (TCRhibcl2hi) subset of CD4+CD8+ thymocytes has selectively terminated CD4 or CD8 synthesis. J Exp Med 184: 2091-2099, 1996.
58. Zaleskis G, Verstovsek S, Tzai TS, Mihich E and Ehrke MJ: Doxorubicin and cyclosporin A affect murine lymphoid cells expressing different antigenic determinants. Oncol Res 7: 307-315, 1995.
59. Ehrke MJ, Verstovsek S, Pocchiari SK, Krawczyk CM, Ujhazy P, Zaleskis G, Maccubbin DL, Meer JM and Mihich E: Thymic anti-tumor effectors in mice cured of lymphoma by cyclophosphamide plus TNF-alpha therapy: Phenotypic and functional characterization up to 20 months after initial tumor inoculation. Int J Cancer 76: 579-586, 1998.
60. Rossmann P, Rihova B, Strohalm J and Ulbrich K: Morphology of rat kidney and thymus after native and antibody-coupled cyclosporin A application (reduced toxicity of targeted drug). Folia Microbiol Praha 42: 277-287, 1997.
61. Barsukov VS and Dudka VT: Morphologic diagnosis of various forms of thymus gland diseases in children using morphometry. Arkhiv Patol 59: 48-52, 1997.
62. Braun S and Pantel K: Clinical significance of occult metastatic cells in bone marrow of breast cancer patients. Oncologist 6: 125-132, 2001.
63. Diel IJ: Bone marrow staging for breast cancer: Is it better than axillary node dissection? Semin Oncol 28: 236-244, 2001.
64. Feuerer M, Beckhove P, Bai L, Solomayer EF, Bastert G, Diel IJ, Pedain C, Oberniedermayr M, Schirrmacher V and Umansky V: Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med 7: 452-458, 2001.
65. Schwartz GN, Warren MK, Rothwell SW, Zujewski J, Halverson DC, Cowan KH, Tolcher A, O'Shaughnessy J and Gress RE: Postchemotherapy and cytokine pretreated marrow stromal layers suppress hematopoiesis from normal donor CD34+ cells. Bone Marrow Transplant 22: 457-468, 1998.
66. Seredenin SB, Durnev AD and Nesterova EV: The influence of verapamil on the clastogenic effect of cyclophosphane in somatic cells from BALB/c and C57B1/6 mice. Eksp Klin Farmakol 62: 51-54, 1999.
67. De Veerman M, Heirman C, Van Meirvenne S, Devos S, Corthals J, Moser M and Thielemans K: Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity. J Immunol 162: 144-151, 1999.
68. Bursch W, Ellinger A, Gerner C, Frohwein U and Schulte-Hermann R: Programmed cell death (PCD). Apoptosis, autophagic PCD, or others? Ann NY Acad Sci 9: 261-212, 2000.
69. Puck JM and Sneller MC: ALPS: An autoimmune human lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Semin Immunol 9: 77-84, 1997.
70. Rieux-Laucat F, Blachere S, Danielan D, De Villartay JP, Oleastro M, Solary E, Bader-Meunier B, Arkwright P, Pondare C, Bermaudin F, Chapel H, Nielsen S, Berrah M, Fischer A and Le Deist F: Lymphoproliferative syndrome with autoimmunity: A possible genetic basis for dominant expression of the clinical manifestations. Blood 94: 2575-2582, 1999.
71. Hanlon MG, Gacis ML, Kakakios AM and Kilham H: Investigation of suspected deficient Fas-mediated apoptosis in a father and son. Cytometry 43: 195-198, 2001.
72. Chiarugi V and Ruggiero M: Role of three cancer "master genes" p53, bcl-2 and c-myc on the apoptotic process. Tumori 82: 205-209, 1996.
73. Gibson LF, Fortney J, Magro G, Ericson SG, Lynch JP and Landreth KS: Regulation of BAX and BCL-2 expression in breast cancer cells by chemotherapy. Breast Cancer Res Treat 55: 107-117, 1999.
74. Collecchi P, Baldini E, Giannessi P, Naccarato AG, Passoni A, Gardin G, Roncella M, Evangelista G, Bevilacqua G and Conte PF: Primary chemotherapy in locally advanced breast cancer (LABC): Effects on tumour proliferative activity, bcl-2 expression and the relationship between tumour regression and biological markers. Eur J Cancer 34: 1701-1704, 1998.
75. Rein DT, Schondorf T, Breidenbach M, Janat MM, Weikelt A, Gohring UJ, Becker M, Mallmann P and Kurbacher CM: Lack of correlation between P53 expression, BCL-2 expression, apoptosis and ex vivo chemosensitivity in advanced human breast cancer. Anticancer Res 20: 5069-5072, 2000.
76. Gutierrez LS, Eliza M, Niven-Fairchild T, Naftolin F and Mor G: The Fas/Fas-ligand system: A mechanism for immune evasion in human breast carcinomas. Breast Cancer Res Treat 54: 245-253, 1999.
77. Zusman I, Gurevich P, Gurevich E and Ben-Hur H: The immune system, apoptosis and apoptosis-related proteins in human ovarian tumors. Int J Oncol 18: 965-972, 2001.
78. O'Connell J, Bennett MW, O'Sullivan GC, O'Callaghan J, Collins JK and Shanahan F: Expression of Fas (CD95/APO-1) ligand by human breast cancers: Significance for tumor immune privilege. Clin Diagn Lab Immunol 6: 457-463, 1999.
79. Shao ZM, Li J, Wu J, Han QX, Shen ZZ, Fontana JA and Barsky SH: Neo-adjuvant chemotherapy for operable breast cancer induces apoptosis. Breast Cancer Res Treat 53: 263-269, 1999.
80. Lopes EC, Garcia MG, Vellon L, Alvarez E and Hajos SE: Correlation between decreased apoptosis and multidrug resistance (MDR) in murine leukemic T cell lines. Leuk Lymphoma 42: 775-787, 2001.
81. Schwartz PS and Waxman DJ: Cyclosphosphamide induces caspase-dependent apoptosis in 9L tumor cells. Mol Pharmacol 60: 1268-1279, 2001.
82. Kaledin VI, Nikolin VP, Ageeva TA, Timofeeva OA, Filipenko ML, Ronichevskaia GM, Morozkova TS, Popova NA and Baimak TI: Cyclosphosphamide induced apoptosis of murine lymphosarcoma cells in vivo. Vopr Onkol 46: 588-593, 2000.
83. Djanayeva SJ, Korolenko TA, Svechnikova IG, Falameyeva OV, Korolenko E, Kaledin VI and Nowicky J: Influence of Ukrain and cyclophosphamide administration on HA-1 murine hepatoma and LS lymphoma on aspartic proteinase cathepsin D. Drugs Exp Clin Res 26: 293-299, 2000.
84. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS and Folkman G: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60: 1878-1886, 2000.
85. Dowsett M, Archer C, Asserosohn L, Gregory RK, Ellis PA, Salter J, Chang J, Mainwaring P, Boeddinghaus I, Johnston SR, Powles TJ and Smith IE: Clinical studies of apoptosis and proliferation in breast cancer. Endocr Relat Cancer 6: 25-28, 1999.